A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

The UMass Chan Medical School in Worcester announced Thursday it received a $35 million gift that aims to advance research to ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Rodriguez is one of over a thousand people with speech difficulties who have cloned their voices using free software from ...

He was diagnosed with Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS). The fatal disease causes muscle weakness, ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The Type ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...